Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics, Inc (RNTX)
:RNTX
RNTX Stock Chart & Stats
$1.28
--
Market closed
$1.28
--
Day’s Range― - ―
52-Week Range$1.04 - $3.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)231.22K
Market Cap
$37.33M
Enterprise Value$71.14M
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Apr 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding26,286,383
10 Day Avg. Volume251,596
30 Day Avg. Volume231,225
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.17
Forecast
1Y Price Target
$8.00Price Target Upside525.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DevelopmentsFDA lifted the full clinical hold on the U.S. Phase 2 RENEW trial, allowing the company to resume enrollment across approximately 20 U.S. sites.
Financial PositionSecured up to $21M in flexible non-dilutive and equity-based financing capacity to support operational runway for Phase 2.
Pipeline PotentialThe stock is fundamentally undervalued given the company’s potential best-in-class pipeline, which targets significant market opportunities lacking effective or tolerable treatments.
Bears Say
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics, Inc’s price range in the past 12 months?
Rein Therapeutics, Inc lowest stock price was $1.04 and its highest was $3.50 in the past 12 months.
What is Rein Therapeutics, Inc’s market cap?
Rein Therapeutics, Inc’s market cap is $37.33M.
When is Rein Therapeutics, Inc’s upcoming earnings report date?
Rein Therapeutics, Inc’s upcoming earnings report date is Apr 06, 2026 which is in 104 days.
How were Rein Therapeutics, Inc’s earnings last quarter?
Rein Therapeutics, Inc released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.03.
Is Rein Therapeutics, Inc overvalued?
According to Wall Street analysts Rein Therapeutics, Inc’s price is currently Undervalued.
Does Rein Therapeutics, Inc pay dividends?
Rein Therapeutics, Inc does not currently pay dividends.
What is Rein Therapeutics, Inc’s EPS estimate?
Rein Therapeutics, Inc’s EPS estimate is -0.22.
How many shares outstanding does Rein Therapeutics, Inc have?
Rein Therapeutics, Inc has 26,286,383 shares outstanding.
What happened to Rein Therapeutics, Inc’s price movement after its last earnings report?
Rein Therapeutics, Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Rein Therapeutics, Inc?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.31%
12-Months-Change
Fundamentals
Return on Equity
-83.28%
Trailing 12-Months
Asset Growth
-48.47%
Trailing 12-Months
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(525.00% Upside)
Technical Analysis
Sonnet BioTherapeutics Holdings
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
7.18% Insiders
3.57% Mutual Funds
21.09% Other Institutional Investors
63.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---